Abstract
Trauma, surgery, and infection represent a common source of stress in critically ill patients admitted in intensive care units (ICUs). Although the consequences of stress response in critical illness are still debated and not well understood, many neural and hormonal responses have been recognized to activate homeostatic mechanisms aimed at favoring survival and healing. These responses develop toward three different phases: the first immediate and short (24 h) phase, termed ebb, is directed to immediate survival; the second longer phase (6–7 days), termed flow, is characterized by an increase in total body oxygen consumption and carbon dioxide production with hypermetabolism; the third phase, termed chronic, may last some months and identifies the post-stress period of critical illness. Although the effects of sedatives (analgesics and hypnotics) on tissue metabolic demand of critically ill patient remain difficult to be adequately defined, these drugs commonly delivered in intensive care units actually influence the stress response by decreasing neurohumoral reactions, involving the sympathetic system, and affecting the inflammatory mechanisms. After the neuroendocrine activation, uncontrolled metabolic reactions, characterized by catabolism and the resistance to anabolic signals as insulin, develop. Secondary negative effects (infections, muscle atrophy and weakness, respiratory insufficiency, delayed wound healing) can occur as direct consequences of metabolic phenomena that are clearly difficult to monitor. Finally, sedatives administered to control stress response clearly have detrimental effects (hemodynamic alterations, immunosuppression, delirium) that should be carefully evaluated in the context of a balance between benefits and damages.
“Today there is a greater and growing awareness of the need to understand the disturbed metabolism and homeostatic mechanisms which come into play when man is injured, whether by accident or surgery, and how these reactions may be assisted in relation to improving the patient’s condition.”
D. P. Cuthbertson, 1975
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cuthbertson DP. Observations on the disturbances of metabolism produced by injury to the limbs. Q J Med. 1932;4:233–44.
Moore FD, Olsen KH, McMurray JD. The body cell mass and its supporting environment. Philadelphia: W B Saunders; 1978.
Kohl BA, Deutschman CS. The inflammatory response to surgery and trauma. Curr Opin Crit Care. 2006;12:325–32.
Preiser JC, Ichal C, Orban C, et al. Metabolic response to the stress of critical illness. Br J Anaesth. 2014;6:945–54.
Kumba C, Van der Linden P. Effects of sedative agents on metabolic demand. Ann Fr Anesth Reanim. 2008;27:574–80.
Kurosawa S, Kato M. Anesthetics, immune cells, and immune responses. J Anesth. 2008;22:263–77.
Beishuizen A, Thijs LG. The immunoneuroendocrine axis in critical illness: beneficial adaptation or neuroendocrine exhaustion? Curr Opin Crit Care. 2004;10:461–7.
Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–67.
Weelers F, Giulietti AP, Michalad M, et al. Metabolic, endocrine immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. Endocrinology. 2003;44:329–38.
Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016;353:i1585.
Nematy M, Brynes AE, Hornick PI, et al. Postprandial ghrelin suppression is exaggerated following major surgery; implications for nutritional recovery. Nutr Metab. 2007;4:20–2.
Forceville X, Vitoux D, Gauzit R, et al. Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients. Crit Care Med. 1998;26:1536–44.
Presier JC, van Zanten A, Berger MM, et al. Metabolic and nutritional support of critically ill patients: consensus and controversies. Crit Care. 2015;19:35–46.
Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011;365:506–17.
Turina M, Fry DE, Polk HC Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med. 2005;33:1624–33.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–25.
Weekers F, Giulietti AP, Michalaki M, et al. Metabolic, endocrine, and immune effects of stress hyperglycemia in rabbit model of prolonged critical illness. Endocrinology. 2003;144:329–38.
Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88:1082–9.
Vlasselaers D, Milants I, Desmet L, et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet. 2009;373:547–56.
Ellger B, Debaveye Y, Vanhorebeek I, et al. Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes. 2006;55:1096–105.
Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310:1591–600.
McClave SA, Martindale RG, Kiraly L. The use of indirect calorimetry in the intensive care unit. Curr Opin Clin Nutr Metab Care. 2013;16:202–8.
Vincent JL, Preiser JC. When should we add parenteral to enteral nutrition? Lancet. 2013;381:354–5.
Heidegger CP, Berger MM, Graf S, et al. Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet. 2013;381:385–93.
Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycemia. Lancet. 2009;373:1798–807.
Mistraletti G, Donatelli F, Carli F. Metabolic and endocrine effects of sedative agents. Curr Opin Crit Care. 2005;11:312–7.
Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41:263–306.
Chen L, Meng K, Su W, et al. The effect of continuous sedation therapy on immunomodulation, plasma levels of antioxidants and indicators of tissue repairs in post-burn sepsis. Cell Biochem Biophys. 2015;73:473–8.
Porhomayon J, El-Solh AA, Adiparvar G, et al. Impact of sedation on cognitive function in mechanically ventilated patients. Lung. 2016;194:43–52.
Barrett JE, Haas DA. Perspectives and trends in pharmacological approaches to the modulation of pain. Adv Pharmacol. 2016;75:1–33.
Hughes CG, McGrane S, Pandharipande P. Sedation in the intensive care setting. Clin Pharmacol. 2012;4:53–63.
Marana E, Russo A, Colicci S, et al. Desflurane versus sevoflurane: a comparison on stress response. Minerva Anestesiol. 2013;79:7–14.
Marana E, Annetta MG, Meo F, et al. Sevoflurane improves the neuroendocrine stress response during laparoscopic pelvic surgery. Can J Anaesth. 2003;50(4):348–54.
Soukup J, Selle A, Wienke A, Steighardt J, et al. Efficiency and safety of inhalative sedation with sevoflurane in comparison to an intravenous sedation concept with propofol in intensive patients: study protocol for a randomized controlled trial. Trials. 2012;13:135–42.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
De Gaudio, A.R., Bonifazi, M., Romagnoli, S. (2018). The Stress Response of Critical Illness: Which Is the Role of Sedation?. In: De Gaudio, A., Romagnoli, S. (eds) Critical Care Sedation. Springer, Cham. https://doi.org/10.1007/978-3-319-59312-8_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-59312-8_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-59311-1
Online ISBN: 978-3-319-59312-8
eBook Packages: MedicineMedicine (R0)